Use este identificador para citar o ir al link de este elemento: http://hdl.handle.net/1843/47164
Registro completo de metadatos
Campo DCValorIdioma
dc.creatorAline Silva de Mirandapt_BR
dc.creatorAmanda Silva de Mirandapt_BR
dc.creatorAntonio Lucio Teixeira Juniorpt_BR
dc.date.accessioned2022-11-10T23:34:31Z-
dc.date.available2022-11-10T23:34:31Z-
dc.date.issued2019-
dc.citation.volume14pt_BR
dc.citation.issue2pt_BR
dc.citation.spage179pt_BR
dc.citation.epage190pt_BR
dc.identifier.doihttps://doi.org/10.1080/17460441.2019.1553951pt_BR
dc.identifier.issn17460441pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/47164-
dc.description.resumoIntroduction: Lamotrigine (LTG) is a well-established anticonvulsant that is also approved for the prevention of mood relapses in bipolar disorder. However, the mechanisms underlying LTG mood stabilizing effects remain unclear. Areas covered: Herein, the pre-clinical evidence concerning LTG’s’ mode of action in depression and mania is reviewed. Bottlenecks and future perspectives for this expanding and promising field are also discussed. Pre-clinical studies have indicated that neurotransmitter systems, especially serotoninergic, noradrenergic and glutamatergic, as well as non-neurotransmitter pathways such as inflammation and oxidative processes might play a role in LTG’s antidepressant effects. The mechanisms underlying LTG’s anti-manic properties remain to be fully explored, but the available pre-clinical evidence points out to the role of glutamatergic neurotransmission, possibly through AMPA-receptors. Expert opinion: A major limitation of current pre-clinical investigations is that there are no experimental models that recapitulate the complexity of bipolar disorder. Significant methodological differences concerning time and dose of LTG treatment, administration route, animal strains, and behavioral paradigms also hamper the reproducibility of the findings, leading to contradictory conclusions. Moreover, the role of other mechanisms (e.g. inositol phosphate and GSK3β pathways) implicated in the mode of action of different mood-stabilizers must also be consolidated with LTG.pt_BR
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológicopt_BR
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Geraispt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentICB - DEPARTAMENTO DE MORFOLOGIApt_BR
dc.publisher.departmentICX - DEPARTAMENTO DE QUÍMICApt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofExpert Opinion on Drug Discoverypt_BR
dc.rightsAcesso Restritopt_BR
dc.subjectLamotriginept_BR
dc.subjectBipolar depressionpt_BR
dc.subjectDisorder bipolarpt_BR
dc.subjectManiapt_BR
dc.subjectSerotoninpt_BR
dc.subjectDopaminept_BR
dc.subjectGlutamatept_BR
dc.subjectBDNFpt_BR
dc.subjectBcl-2pt_BR
dc.subjectAnimal modelspt_BR
dc.subject.otherTranstorno bipolarpt_BR
dc.subject.otherDepressão mentalpt_BR
dc.subject.otherDopaminapt_BR
dc.subject.otherGlutamato monossódicopt_BR
dc.subject.otherSerotoninapt_BR
dc.subject.otherDistúrbios cognitivospt_BR
dc.subject.otherModelos animaispt_BR
dc.titleLamotrigine as a mood stabilizer: insights from the pre-clinical evidencept_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.tandfonline.com/doi/abs/10.1080/17460441.2019.1553951?journalCode=iedc20pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0003-2811-7924pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-8887-2772pt_BR
dc.identifier.orcidAntonio Lucio Teixeira Juniorpt_BR
Aparece en las colecciones:Artigo de Periódico

archivos asociados a este elemento:
no existem archivos asociados a este elemento.


Los elementos en el repositorio están protegidos por copyright, con todos los derechos reservados, salvo cuando es indicado lo contrario.